Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The chaperonin CCT inhibits assembly of α-synuclein amyloid fibrils by a specific, conformation-dependent interaction

  • Sot, Begoña
  • Rubio-Muñoz, Alejandra
  • Leal-Quintero, Ahudrey
  • Martínez-Sabando, Javier
  • Marcilla, Miguel
  • Roodveldt, Cintia
  • Valpuesta, José M.
The eukaryotic chaperonin CCT (chaperonin containing TCP-1) uses cavities built into its double-ring structure to encapsulate and to assist folding of a large subset of proteins. CCT can inhibit amyloid fibre assembly and toxicity of the polyQ extended mutant of huntingtin, the protein responsible for Huntington's disease. This raises the possibility that CCT modulates other amyloidopathies, a still-unaddressed question. We show here that CCT inhibits amyloid fibre assembly of α-synuclein A53T, one of the mutants responsible for Parkinson's disease. We evaluated fibrillation blockade in α-synuclein A53T deletion mutants and CCT interactions of full-length A53T in distinct oligomeric states to define an inhibition mechanism specific for α-synuclein. CCT interferes with fibre assembly by interaction of its CCT and CCT 3 subunits with the A53T central hydrophobic region (NAC). This interaction is specific to NAC conformation, as it is produced once soluble α-synuclein A53T oligomers form and blocks the reaction before fibres begin to grow. Finally, we show that this association inhibits α-synuclein A53T oligomer toxicity in neuroblastoma cells. In summary, our results and those for huntingtin suggest that CCT is a general modulator of amyloidogenesis via a specific mechanism., This work was supported by grants RYC2011-08746 (to BS), RTC-2015-3309-1 (to CR) and BFU2016-75984 (to JMV) from the Spanish Ministry of Economy, the Bolsa de Investigación L’Oréal-UNESCO 2013 (to BS), CP10/00527 from Spanish Ministry of Health (to CR) and grant S2013/MIT-2807 from the Madrid Regional Government (to JMV)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Immunization with α-synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model

  • Villadiego, Javier
  • Labrador-Garrido, Adahir
  • Franco, Jaime M.
  • Leal-Lasarte, María M.
  • De Genst, Erwin J.
  • Dobson, Christopher M.
  • Pozo, David
  • Toledo-Aral, Juan José
  • Roodveldt, Cintia
Neuroinflammation mediated by chronically activated microglia, largely caused by abnormal accumulation of misfolded α-synuclein (αSyn) protein, is known to contribute to the pathophysiology of Parkinson's disease (PD). In this work, based on the immunomodulatory activities displayed by particular heat-shock proteins (HSPs), we tested a novel vaccination strategy that used a combination of αSyn and Grp94 (HSPC4 or Gp96) chaperone and a murine PD model. We used two different procedures, first, the adoptive transfer of splenocytes from αSyn/Grp94-immunized mice to recipient animals, and second, direct immunization with αSyn/Grp94, to study the effects in a chronic mouse MPTP-model of parkinsonism. We found that both approaches promoted a distinct profile in the peripheral system—supported by humoral and cellular immunity—consisting of a Th1-shifted αSyn-specific response accompanied by an immune-regulatory/Th2-skewed general phenotype. Remarkably, this mixed profile sustained by αSyn/Grp94 immunization led to strong suppression of microglial activation in the substantia nigra and striatum, pointing to a newly described positive effect of anti-αSyn Th1-responses in the context of PD. This strategy is the first to target αSyn and report the suppression of PD-associated microgliosis. Overall, we show that the αSyn/Grp94 combination supports a distinct and long-lasting immune profile in the peripheral system, which has an impact at the CNS level by suppressing chronic microglial activation in an MPTP model of PD. Furthermore, our study demonstrates that reshaping peripheral immunity by vaccination with appropriate misfolding protein/HSP combinations could be highly beneficial as a treatment for neurodegenerative misfolding diseases., Grant sponsor: Spanish Ministry of Economy, and cofunded by Fonds Europeen de Developpement Economique et Regional (FEDER): CP10/00527, SAF2012-39720 and RTC-2015-3309-1 (to CR); PI12/02574-ISCIII, Red TerCel ISCIII (RD12/0019/0033 and RD16/0011/0025) and RTC-2015-3309-1 (to JJTA); PI14/01600-ISCIII (to DP); P12-CTS-2739 (to JJTA) and P11-CTS8161 (to DP) from the Regional Ministry of Economy. The work of CMD and EJDG was supported by the Cambridge Center for Misfolding Diseases. CR holds a senior Servet II contract (CPII16/58) from the Spanish Ministry of Economy (Instituto de Salud Carlos III) cofounded by FEDER., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies

  • Artigas, Francesc
  • Celada, Pau
  • Bortolozzi, Analía
In the second part we focus on two treatment strategies that may overcome the main limitations of current antidepressant drugs. First, we review the experimental and clinical evidence supporting the use of glutamatergic drugs as fast-acting antidepressants. Secondly, we review the involvement of microRNAs (miRNAs) in the pathophysiology of major depressive disorder (MDD) and the use of small RNAs (e.g.., small interfering RNAs or siRNAs) to knockdown genes in monoaminergic and non-monoaminergic neurons and induce antidepressant-like responses in experimental animals. The development of glutamatergic agents is a promising venue for antidepressant drug development, given the antidepressant properties of the non-competitive NMDA receptor antagonist ketamine. Its unique properties appear to result from the activation of AMPA receptors by a metabolite [(2 S,6 S;2 R,6 R)-hydroxynorketamine (HNK)] and mTOR signaling. These effects increase synaptogenesis in prefrontal cortical pyramidal neurons and enhance serotonergic neurotransmission via descending inputs to the raphe nuclei. This view is supported by the cancellation of ketamine's antidepressant-like effects by inhibition of serotonin synthesis. We also review existing evidence supporting the involvement of miRNAs in MDD and the preclinical use of RNA interference (RNAi) strategies to target genes involved in antidepressant response. Many miRNAs have been associated to MDD, some of which e.g., miR-135 targets genes involved in antidepressant actions. Likewise, SSRI-conjugated siRNA evokes faster and/or more effective antidepressant-like responses. Intranasal application of sertraline-conjugated siRNAs directed to 5-HT1A receptors and SERT evoked much faster changes of pre- and postsynaptic antidepressant markers than those produced by fluoxetine., Support from the following grants is acknowledged: SAF2015-68346-P, SAF2016-75797-R and Retos-Colaboración Subprogram RTC-2015–3309-1, MINECO co-financed by European Regional Development Fund - ERDF), UE (Ministry of Economy and Competitiveness and European Regional Development Fund), PI12/00156, PI16/00287 and PI13/01390 (Instituto de Salud Carlos III, co-financed by ERDF, "A way to build Europe"), and Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM. Support from the Generalitat de Catalunya (2014SGR798 and 2017SGR717) is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Selective Knockdown of TASK3 Potassium Channel in Monoamine Neurons: a New Therapeutic Approach for Depression

  • Fullana, Neus
  • Ferrés-Coy, Albert
  • Ortega, Jorge E.
  • Ruiz-Bronchal, Esther
  • Paz, Verónica
  • Meana, J. Javier
  • Artigas, Francesc
  • Bortolozzi, Analía
Current pharmacological treatments for major depressive disorder (MDD) are severely compromised by both slow action and limited efficacy. RNAi strategies have been used to evoke antidepressant-like effects faster than classical drugs. Using small interfering RNA (siRNA), we herein show that TASK3 potassium channel knockdown in monoamine neurons induces antidepressant-like responses in mice. TASK3-siRNAs were conjugated to cell-specific ligands, sertraline (Ser) or reboxetine (Reb), to promote their selective accumulation in serotonin (5-HT) and norepinephrine (NE) neurons, respectively, after intranasal delivery. Following neuronal internalization of conjugated TASK3-siRNAs, reduced TASK3 mRNA and protein levels were found in the brainstem 5-HT and NE cell groups. Moreover, Ser-TASK3-siRNA induced robust antidepressant-like behaviors, enhanced the hippocampal plasticity, and potentiated the fluoxetine-induced increase on extracellular 5-HT. Similar responses, yet of lower magnitude, were detected for Reb-TASK3-siRNA. These findings provide substantial support for TASK3 as a potential target, and RNAi-based strategies as a novel therapeutic approach to treat MDD., This work was supported by the following grants: SAF2015-68346-P (F.A.); SAF2013-48586-R (J.M.); SAF2016-75797-R (A.B.); Retos-Colaboración Subprograms RTC-2014-2812-1 and RTC-2015-3309-1 (A.B.); Ministry of Economy and Competitiveness (MINECO)—European Regional Development Fund (ERDF), UE; PI13/01390, Instituto de Salud Carlos III co-financed by ERDF (A.B.); IT616-13 Basque Government—ERDF (J.M.); 20003 NARSAD Independent Investigator (A.B.); and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM). CERCA Programme/Generalitat de Catalunya is also acknowledged. M.N.F. and A.F-C. are recipients of a fellowship from the Spanish Ministry of Education, Culture and Sport., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Regionally selective knockdown of astroglial glutamate transporters in infralimbic cortex induces a depressive phenotype in mice

  • Fullana, Neus
  • Ruiz-Bronchal, Esther
  • Ferrés-Coy, Albert
  • Juárez-Escoto, Elena
  • Artigas, Francesc
Elevation of energy metabolism and disturbance of astrocyte number/function in the ventral anterior cingulate cortex (vACC) contributes to the pathophysiology of major depressive disorder (MDD). Functional hyperactivity of vACC may result from reduced astrocytic glutamate uptake and increased neuronal excitation. Here we tested this hypothesis by knocking‐down astrocytic glutamate transporter GLAST/GLT‐1 expression in mouse infralimbic (IL, rodent equivalent of vACC) or prelimbic (PrL) cortices using RNAi strategies. Unilateral siRNA (small interfering RNA) microinfusion targeting GLAST or GLT‐1 in mouse IL induced a moderate (20–30%) and long‐lasting (7 days) decrease in their expression. Intra‐IL GLAST‐/GLT‐1 siRNA microinfusion reduced the number of glial fibrillary acidic protein (GFAP)‐positive and glutamine synthetase (GS)‐positive astrocytes and evoked a depressive‐like phenotype reversed by citalopram and ketamine. Intra‐IL GLAST or GLT‐1 knockdown markedly reduced serotonin (5‐HT) release in the dorsal raphe nucleus (DR) and induced an overall reduction of brain‐derived neurotrophic factor (BDNF) expression in ipsilateral and contralateral hemispheres. Egr‐1 (early growth response protein‐1) labeling suggests that both siRNAs enhance the GABAergic tone onto DR 5‐HT neurons, leading to an overall decrease of 5‐HT function, likely related to the widespread reduction on BDNF expression. Conversely, similar reductions of GLAST and GLT‐1 expression in PrL did not induce a depressive‐like phenotype. These results suggest that a focal glial change in IL translates into global change of brain activity by virtue of the descending projections from IL to DR and the subsequent attenuation of serotonergic function in forebrain, an effect perhaps related to the varied symptomatology of MDD., This study was supported by the Spanish Ministry of Economy and Competitiveness, SAF2015‐68346‐P (F.A.) and SAF2016‐75797‐R (A.B.); Retos‐Colaboración Subprogram RTC‐2015‐3309‐1 (A.B.) cofinanced by the European Regional Development Fund “A way to build Europe”. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and CERCA Programme/Generalitat de Catalunya is also acknowledged. N.F. is a recipient of a fellowship from Spanish Ministry of Education, Culture, and Sport., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Differential Interactome and Innate Immune Response Activation of Two Structurally Distinct Misfolded Protein Oligomers

  • Mannini, Benedetta
  • Vecchi, Giulia
  • Labrador-Garrido, Adahir
  • Fabre, Bertrand
  • Fani, Giulia
  • Franco, Jaime M.
  • Lilley, Kathryn
  • Pozo, David
  • Vendruscolo, Michele
  • Chiti, Fabrizio
  • Dobson, Christopher M.
  • Roodveldt, Cintia
The formation of misfolded protein oligomers during early stages of amyloid aggregation and the activation of neuroinflammatory responses are two key events associated with neurodegenerative diseases. Although it has been established that misfolded oligomers are involved in the neuroinflammatory process, the links between their structural features and their functional effects on the immune response remain unknown. To explore such links, we took advantage of two structurally distinct soluble oligomers (type A and B) of protein HypF-N and compared the elicited microglial inflammatory responses. By using confocal microscopy, protein pull-down, and high-throughput mass spectrometry, we found that, even though both types bound to a common pool of microglial proteins, type B oligomers - with a lower solvent-exposed hydrophobicity - showed enhanced protein binding, correlating with the observed inflammatory response. Furthermore, the interactome associated with inflammatory-mediated neurodegeneration revealed previously unidentified receptors and signaling molecules likely to be involved in the oligomer-elicited innate immune response., Financial support was provided by FEBS (Short-Term Fellowship to B.M.), EMBO (ASTF 450-2013 to B.M.), the Italian Society of Biochemistry and Molecular Biology (B.M.), the Spanish Ministry of Economy (RTC-2015-3309-1 to C.R., ISCIII CPII16/58 to C.R., PI14-1600 to D.P., and RTI2018- 098432-B-I00 to C.R. and D.P.), the Regional Ministry of Economy (P11-CTS-8161 and PAIDI2020 CTS-677 to D.P.), Programa “Atraccion de Talento ́ ”, University of Seville, and Programa “Ramon y Cajal ́ ”, Spanish Ministry of Economy (RYC-2017-23127 to C.R.). This work was also supported by the Cambridge Centre for Misfolding Diseases (B.M., G.V., G.F., M.V., C.M.D.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys

  • Alarcón-Arís, Diana
  • Pavia-Collado, Rubén
  • Miquel-Rio, Lluís
  • Coppola-Segovia, Valentín
  • Ferrés-Coy, Albert
  • Ruiz-Bronchal, Esther
  • Galofré, Mireia
  • Paz, Verónica
  • Campa, Leticia
  • Revilla, Raquel
  • Montefeltro, Andrés
  • Kordower, Jeffrey H.
  • Vila, M.
  • Artigas, Francesc
  • Bortolozzi, Analía
Background: Progressive neuronal death in monoaminergic nuclei and widespread accumulation of α-synuclein are neuropathological hallmarks of Parkinson's disease (PD). Given that α-synuclein may be an early mediator of the pathological cascade that ultimately leads to neurodegeneration, decreased α-synuclein synthesis will abate neurotoxicity if delivered to the key affected neurons. Methods: We used a non-viral gene therapy based on a new indatraline-conjugated antisense oligonucleotide (IND-ASO) to disrupt the α-synuclein mRNA transcription selectively in monoamine neurons of a PD-like mouse model and elderly nonhuman primates. Molecular, cell biology, histological, neurochemical and behavioral assays were performed. Findings: Intracerebroventricular and intranasal IND-ASO administration for four weeks in a mouse model with AAV-mediated wild-type human α-synuclein overexpression in dopamine neurons prevented the synthesis and accumulation of α-synuclein in the connected brain regions, improving dopamine neurotransmission. Likewise, the four-week IND-ASO treatment led to decreased levels of endogenous α-synuclein protein in the midbrain monoamine nuclei of nonhuman primates, which are affected early in PD. Conclusions: : The inhibition of α-synuclein production in dopamine neurons and its accumulation in cortical/striatal projection areas may alleviate the early deficits of dopamine function, showing the high translational value of antisense oligonucleotides as a disease modifying therapy for PD and related synucleinopathies., Grants SAF2016-75797-R, RTC-2014-2812-1 and RTC-2015-3309-1, Ministry of Economy and Competitiveness (MINECO) and European Regional Development Fund (ERDF), UE; Grant ID 9238, Michael J. Fox Foundation; and Centres for Networked Biomedical Research on Mental Health (CIBERSAM), and on Neurodegenerative Diseases (CIBERNED).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice

  • Pavia-Collado, Rubén
  • Coppola-Segovia, Valentín
  • Miquel-Rio, Lluís
  • Alarcón-Arís, Diana
  • Rodríguez-Aller, Raquel
  • Torres-López, María
  • Paz, Verónica
  • Ruiz-Bronchal, Esther
  • Campa, Leticia
  • Artigas, Francesc
  • Montefeltro, Andrés
  • Revilla, Raquel
  • Bortolozzi, Analía
α-Synuclein (α-Syn) protein is involved in the pathogenesis of Parkinson’s disease (PD). Point mutations and multiplications of the α-Syn, which encodes the SNCA gene, are correlated with early-onset PD, therefore the reduction in a-Syn synthesis could be a potential therapy for PD if delivered to the key affected neurons. Several experimental strategies for PD have been developed in recent years using oligonucleotide therapeutics. However, some of them have failed or even caused neuronal toxicity. One limiting step in the success of oligonucleotide-based therapeutics is their delivery to the brain compartment, and once there, to selected neuronal populations. Previously, we developed an indatraline-conjugated antisense oligonucleotide (IND-1233-ASO), that selectively reduces α-Syn synthesis in midbrain monoamine neurons of mice, and nonhuman primates. Here, we extended these observations using a transgenic male mouse strain carrying both A30P and A53T mutant human α-Syn (A30P*A53T*α-Syn). We found that A30P*A53T*α-Syn mice at 4–5 months of age showed 3.5-fold increases in human α-Syn expression in dopamine (DA) and norepinephrine (NE) neurons of the substantia nigra pars compacta (SNc) and locus coeruleus (LC), respectively, compared with mouse α-Syn levels. In parallel, transgenic mice exhibited altered nigrostriatal DA neurotransmission, motor alterations, and an anxiety-like phenotype. Intracerebroventricular IND-1233-ASO administration (100 µg/day, 28 days) prevented the α-Syn synthesis and accumulation in the SNc and LC, and recovered DA neurotransmission, although it did not reverse the behavioral phenotype. Therefore, the present therapeutic strategy based on a conjugated ASO could be used for the selective inhibition of α-Syn expression in PD-vulnerable monoamine neurons, showing the benefit of the optimization of ASO molecules as a disease modifying therapy for PD and related α-synucleinopathies., This study was supported by grants SAF2016-75797-R, PID2019-105136RB-100, Retos- Colaboración Subprogram RTC-2015-3309-1, Ministry of Economy and Competitiveness (MINECO) and European Regional Development Fund (ERDF), UE; and CB/07/09/0034 Center for Networked Biomedical Research on Mental Health (CIBERSAM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis doctoral (DoctoralThesis)

Proteína alfa-sinucleína y modulación de los sistemas monoaminérgicos. Desde la función fisiológica a diana terapéutica utilizando ácidos nucleicos de interferencia

  • Alarcón-Arís, Diana
Tesis doctoral presentada para lograr el título de Doctor por la Universidad de Barcelona, Programa de Doctorado en Biomedicina.--Calificación: Sobresaliente cum laude, La proteína o-Slnucleína (o-Syn) se expresa de forma abundante en el cerebro, representado aproximadamente el 1% del total de la proteína citosólica, localizada principalmente en las terminales slnápticas. Sin embargo, su rol fisiológico todavía es desconocido. Además, múltiples estudios han demostrado que la acumulación de o­Syn tiene un papel crucial en la neuropatologfa de la enfermedad de Parkinson (PO). Los mecanismos exactos por los cuales o-Syn causa las alteraciones histológicas, que conducen principalmente en la muerte de neuronas mesencefállcas dopaminérgicas (DA), alteraciones en el circuito de los ganglios basales y presencia de síntomas motores y no motores aún no están claros. Se ha sugerido que la toxicidad asociada a o-Syn está mediada por varias formas reactivas de la proteína que afectan a distintos procesos celulares. En la presente Tesis decidimos examinar en primer lugar el rol fisiológico de o-Syn sobre la actividad de los componentes que mantienen la homeostasis de la neurotransmisión monoamlnérgica y, de los procesos de plasticidad y neurogénesis dependientes de inervación DA. En segundo lugar, nos propusimos evaluar la efectividad de RNAs terapéuticos incluyendo RNAs pequeños de interferencia (siRNAs) y oligonucleótidos antisentldo (AS0s) conjugados con indatralina (IND, triple inhlbldor de los transportadres de monoaminas) en modelos murlons de PO y en monos. Concretamente, abordamos la 1) examinaclón de las consecuencias funcionales sobre la neurotransmisión monoaminérglca asociadas a distintos niveles de expresion intracelular de a-Syn en neuronas DA y serotonlnérglcas (5-HT) usando modelos murlnos transgénlcos de sobre-expresión y knockdown Inducidos por secuencias de siRNAs o ASOs; 2) examinación del rol sináptico de o-Syn en los aferentes DA de la sustancia nlgra pars compacta (SNc) sobre los procesos de mantenimiento, auto-renovación y diferenciación de las células neuronales progenitoras, usando modelos murinos nulos para o-Syn o de sobre-expresión inducidos por vectores adenoasoclados (AAV); 3) generación y caracterización de modelos murinos de PD basado en la sobre-expresión de la forma wild-type humana de o-Syn inducido por AAVS en las neuronas DA de la SNc/área tegmental ventral {VfA) o en las neuronas 5-HT de los núcleos del rafe. Examlnación de la eficacia y selectividad de una secuencia específica de ASO conjugada con IND para disminuir la producción de o-Syn en el modelo de sobre-expresión enlas neuronas DA y 5-HT y reversión del fenotipo conductual; y 4) evaluación de la eficacia y selectividad de la secuencia de ASO conjugada con IND para reducir la síntesis de a-Syn en los núcleos monoaminérgicos de monos Rhesus envejecidos. En la presente Tesis demostramos que la proteína a-Syn actúa como regulador sináptico negativo de la neurotransmisión DA y 5-HT en áreas corticales y subcorticales y es un requerimiento esencial para mantener el potencial neurogénico adulto. Además, la conjugación de una secuencia siRNA o ASO especifica contra a-Sin con IND favorece la acumulación in vivo del ollgonucleótido selectivamente en las neuronas monoaminérgicas (DA, NA y 5-HT). La sobre-expresión de la forma humana WT de a-Sin en la SNc/VfA o en los núcleos del rafe de ratón utilizando un vector AAVS recapitula algunos de los síntomas cardinales de la PO. La terapia con ASO conjugado reduce los niveles de a-Syn en los modelos de sinucleinopatía en las neuronas DA de la SNc/VTA y 5-HT en los núcleos del rafe asl como en los monos Rhesus, sugiriendo que los RNA terapéuticos no virales pueden convertirse en una estrategia potencial en el tratamiento de la PD., El presente trabajo ha sido financiado por los siguientes proyectos: 1. “Supresión de la expresión de α-sinucleína y de la actividad de PDE10 como estrategia terapéutica combinada para el tratamiento de Parkinson y mejora de las disfunciones cognitivas” con código IPT-2012-1208-300000 y financiado por el Ministerio de Economía y Competitividad (MINECO) y cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER). 2. “Sinucleínas, depresión y enfermedad de Parkinson. Nuevas estrategias terapéuticas basadas en ácidos nucleicos de interferencia” con código PI13/01390 y financiado por el Fondo de Investigación Sanitaria-Instituto de Salud Carlos III y cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER). 3. “Nuevas estrategias terapéuticas para el tratamiento de sinucleinopatías” con código RTC-2014-2812-1 y financiado por el Ministerio de Economía y Competitividad (MINECO) y cofinanciado el Fondo Europeo de Desarrollo Regional (FEDER). 4. “Pharmacokinetic and pharmacodynamic characterization of a novel therapy to silence selectively alpha-synuclein in monoaminergic neurons of rat" con código 9238 y financiado por La Fundación Michael J. Fox. 5. “Desarrollo de una terapia para el tratamiento de variantes genéticas de αsinucleína en la enfermedad de Parkinson” con código RTC-2015-3309-1 y financiado por el Ministerio de Economía y Competitividad (MINECO) y cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER). 6. “Sinucleinopatías y oligonucleótidos inhibitorios: Rol de α- y γ-sinucleínas en la regulación de la función cognitiva” con código SAF2016-75797-R y financiado por el Ministerio de Economía y Competitividad (MINECO) y cofinanciado el Fondo Europeo de Desarrollo Regional (FEDER).